DuPont’s nutrition and bioscience business may be up for sale and Amsterdam’s Royal DSM may want to buy it, according to a report from Bloomberg.
Download Now: To be a profitable investor you first need to know the rules. Get Jim Cramer’s 25 Rules for Investing Special Report
The business could be valued at $25 billion, people who asked not to be identified told Bloomberg.
The specialty chemicals maker has been considering the sale or spinoff of its nutrition business, and has been in the process of selecting advisers to sort out offers for the division for some time, according to confidential sources.
In August, Bloomberg said that DuPont wanted to rid itself of the arm, and may be looking into a Reverse Morris Trust, a tax-free merger, as well.
Shares of DuPont fell 1.41% to $72.50 on Monday.
By Cherella Cox Owoyelu
Source: The Street
With European building block chemical contracts now settling at record decreases, and 32% of European refineries now offline or at reduced operating rates, more evidence of the damage caused by […]
Nouryon has entered into an agreement to acquire the merchant triethyl aluminum (TEAL) business of Sasol, including its specialty fleet of returnable cylinders. TEAL is a metal alkyl essential in […]
At a strategy meeting today with analysts and the press, conducted by phone due to the coronavirus disease 2019 (COVID-19) pandemic, Arkema’s top executives, headed by CEO Thierry Le Hénaff, […]
